Chemomab Therapeutics Ltd DRC (CMMB) - Total Liabilities
Based on the latest financial reports, Chemomab Therapeutics Ltd DRC (CMMB) has total liabilities worth $1.14 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Chemomab Therapeutics Ltd DRC generate cash to assess how effectively this company generates cash.
Chemomab Therapeutics Ltd DRC - Total Liabilities Trend (2012–2024)
This chart illustrates how Chemomab Therapeutics Ltd DRC's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Chemomab Therapeutics Ltd DRC's assets to evaluate the company's liquid asset resilience ratio.
Chemomab Therapeutics Ltd DRC Competitors by Total Liabilities
The table below lists competitors of Chemomab Therapeutics Ltd DRC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SeaStar Medical Holding Corporation
NASDAQ:ICU
|
USA | $4.07 Million |
|
Revenue Group Bhd
KLSE:0200
|
Malaysia | RM92.63 Million |
|
Jwwinvest
WAR:JWW
|
Poland | zł51.00 Million |
|
Nagreeka Exports Limited
NSE:NAGREEKEXP
|
India | Rs2.21 Billion |
|
Wong Engineering Corporation Bhd
KLSE:7050
|
Malaysia | RM54.95 Million |
|
SCANDIN.ENVIRO SYSTEMS AB
F:1HR
|
Germany | €55.26 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Chemomab Therapeutics Ltd DRC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CMMB stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chemomab Therapeutics Ltd DRC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chemomab Therapeutics Ltd DRC (2012–2024)
The table below shows the annual total liabilities of Chemomab Therapeutics Ltd DRC from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.43 Million | -33.51% |
| 2023-12-31 | $5.15 Million | -24.65% |
| 2022-12-31 | $6.84 Million | +136.92% |
| 2021-12-31 | $2.89 Million | +72.46% |
| 2020-12-31 | $1.67 Million | -65.46% |
| 2019-12-31 | $4.85 Million | +63.94% |
| 2018-12-31 | $2.96 Million | +9.64% |
| 2017-12-31 | $2.70 Million | +14.41% |
| 2016-12-31 | $2.36 Million | +71.93% |
| 2015-12-31 | $1.37 Million | -77.87% |
| 2012-12-31 | $6.19 Million | -- |
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing ch… Read more